Why is Germany’s CureVac vaccine just 48% effective? | Covid-19 Special

CureVac’s COVID-19 jab did not turn out what many hoped it would be. That’s despite using the same messenger RNA technology as rivals Moderna and BioNTech-Pfizer.

CureVac aimed to produce its vaccine primarily for developing countries – as it can be stored more easily than other products.

And despite disappointing trial-results the company is sticking to the plan.